What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...
Keytruda and Padcev combination shows improved event-free and overall survival in muscle invasive bladder cancer patients ineligible for cisplatin. The KEYNOTE-905/EV-303 trial demonstrated ...
Preoperative RT with pembrolizumab showed high pathologic complete response rates and notable three-year event-free survival in TNBC and HR+/HER2- patients with breast cancer. PD-L1 expression and ...
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the investigational individualized neoantigen therapy, V940 ...
TORONTO and HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (MDNA) (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today ...
Keytruda Qlex must be administered by a health care provider. The Food and Drug Administration (FDA) has approved Keytruda Qlex ™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients aged 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback